<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Favipiravir (FPV) is the first approved drug by the national medical products administration of China for the treatment of COVID-19 [
 <xref rid="bb0205" ref-type="bibr">41</xref>]. Cai et al. performed an open-Label Control Study of FPV on COVID-19 patients. In these experiments, 35 patients were given treatment of FPV and 45 patients were treated with lopinavir and ritonavir (LPV/RTV) combination. It was found that those treated with FPV appeared to have faster viral clearance and better chest imaging change than patients treated with LPV/RTV [
 <xref rid="bb0210" ref-type="bibr">42</xref>].
</p>
